CORT vs. AMPH
Compare and contrast key facts about Corcept Therapeutics Incorporated (CORT) and Amphastar Pharmaceuticals, Inc. (AMPH).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: CORT or AMPH.
Correlation
The correlation between CORT and AMPH is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
CORT vs. AMPH - Performance Comparison
Key characteristics
CORT:
1.50
AMPH:
-1.06
CORT:
4.18
AMPH:
-1.58
CORT:
1.57
AMPH:
0.80
CORT:
4.35
AMPH:
-0.65
CORT:
12.52
AMPH:
-1.51
CORT:
15.79%
AMPH:
27.99%
CORT:
122.13%
AMPH:
39.33%
CORT:
-94.28%
AMPH:
-64.63%
CORT:
-37.51%
AMPH:
-62.08%
Fundamentals
CORT:
$7.72B
AMPH:
$1.16B
CORT:
$1.23
AMPH:
$3.06
CORT:
59.16
AMPH:
8.01
CORT:
0.61
AMPH:
2.77
CORT:
11.62
AMPH:
1.63
CORT:
11.36
AMPH:
1.63
CORT:
$685.45M
AMPH:
$558.19M
CORT:
$674.70M
AMPH:
$280.64M
CORT:
$111.33M
AMPH:
$203.23M
Returns By Period
In the year-to-date period, CORT achieves a 41.66% return, which is significantly higher than AMPH's -33.61% return. Over the past 10 years, CORT has outperformed AMPH with an annualized return of 28.81%, while AMPH has yielded a comparatively lower 5.38% annualized return.
CORT
41.66%
1.26%
31.45%
181.02%
39.82%
28.81%
AMPH
-33.61%
3.79%
-46.52%
-41.60%
5.60%
5.38%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
CORT vs. AMPH — Risk-Adjusted Performance Rank
CORT
AMPH
CORT vs. AMPH - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and Amphastar Pharmaceuticals, Inc. (AMPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
CORT vs. AMPH - Dividend Comparison
Neither CORT nor AMPH has paid dividends to shareholders.
Drawdowns
CORT vs. AMPH - Drawdown Comparison
The maximum CORT drawdown since its inception was -94.28%, which is greater than AMPH's maximum drawdown of -64.63%. Use the drawdown chart below to compare losses from any high point for CORT and AMPH. For additional features, visit the drawdowns tool.
Volatility
CORT vs. AMPH - Volatility Comparison
Corcept Therapeutics Incorporated (CORT) has a higher volatility of 16.59% compared to Amphastar Pharmaceuticals, Inc. (AMPH) at 13.65%. This indicates that CORT's price experiences larger fluctuations and is considered to be riskier than AMPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
CORT vs. AMPH - Financials Comparison
This section allows you to compare key financial metrics between Corcept Therapeutics Incorporated and Amphastar Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CORT vs. AMPH - Profitability Comparison
CORT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Corcept Therapeutics Incorporated reported a gross profit of 154.81M and revenue of 157.21M. Therefore, the gross margin over that period was 98.5%.
AMPH - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Amphastar Pharmaceuticals, Inc. reported a gross profit of 86.65M and revenue of 186.98M. Therefore, the gross margin over that period was 46.3%.
CORT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Corcept Therapeutics Incorporated reported an operating income of 3.42M and revenue of 157.21M, resulting in an operating margin of 2.2%.
AMPH - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Amphastar Pharmaceuticals, Inc. reported an operating income of 45.14M and revenue of 186.98M, resulting in an operating margin of 24.1%.
CORT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Corcept Therapeutics Incorporated reported a net income of 20.29M and revenue of 157.21M, resulting in a net margin of 12.9%.
AMPH - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Amphastar Pharmaceuticals, Inc. reported a net income of 37.96M and revenue of 186.98M, resulting in a net margin of 20.3%.